CRBP
Corbus Pharmaceuticals Holdings
$10.96
+0.83%
2026-05-08
About Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Key Fundamentals
Forward P/E
-2.25
EPS (TTM)
$-5.90
ROE
-54.2%
Profit Margin
0.0%
Debt/Equity
1.11
Price/Book
1.30
Beta
2.68
Market Cap
$193.0M
Avg Volume (10D)
357K
Recent Breakout Signals
No recent breakout signals detected for CRBP.
Recent Price Range (60 Days)
60D High
$11.36
60D Low
$7.20
Avg Volume
240K
Latest Close
$10.96
Get breakout alerts for CRBP
Sign up for Breakout Scanner to receive daily notifications when CRBP triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Corbus Pharmaceuticals Holdings (CRBP) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CRBP daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CRBP operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.